Medicare GLP-1 rules upend telehealth weight-loss boom

Medicare’s innovative BALANCE Model and the MFN pricing reforms are dramatically lowering costs and expanding access to GLP-1 therapies for obesity and diabetes. By setting Medicare and Medicaid prices around $245 per month—significantly below typical cash prices of $350—and capping beneficiary copays at $50, these reforms dismantle traditional pricing barriers. Notably, the inclusion of future oral GLP-1 formulations in MFN agreements locks in these lower launch prices, disrupting the conventional high-launch, rebate-driven pricing model and posing new challenges for smaller biotech entrants aiming to compete in this lucrative market.

The BALANCE Model, launching in January 2027, represents a paradigm shift in Medicare’s approach to GLP-1 drug coverage by directly negotiating prices and eligibility criteria with manufacturers like Lilly and Novo Nordisk. This model expands patient eligibility beyond type 2 diabetes to include obesity-related comorbidities such as moderate to advanced liver fibrosis and obstructive sleep apnea, using specific BMI thresholds to broaden access. Operating under Section 1115A demonstration authority, BALANCE cleverly circumvents statutory exclusions on weight loss drugs in Medicare Part D, enabling expanded coverage without requiring legislative changes—a move that is forcing unprecedented contract and operational adjustments across pharma, payers, and plans.

The Medicare GLP-1 Bridge demonstration, active from July 2026 through December 2027, serves as a transitional program offering eligible beneficiaries access to select GLP-1 drugs at a flat $50 monthly copay, while operating outside the traditional Part D benefit structure. This arrangement shields Part D plan sponsors from financial risk for these drugs during the demonstration period, smoothing the pathway toward the broader and more durable BALANCE Model. However, the success of BALANCE hinges on mandatory participation, requiring at least 80% of Medicare Part D plan sponsors to join to avoid adverse selection, effectively compelling near-universal buy-in and reshaping the competitive landscape for plans.

While these Medicare pricing reforms significantly benefit patients by lowering out-of-pocket costs and expanding access, they also compress rebate spreads traditionally earned by pharmacy benefit managers (PBMs), thereby squeezing their margins and complicating formulary negotiations. This compression exposes employer-sponsored plans to heightened fiduciary scrutiny under ERISA, as publicly visible benchmark prices around $245 per month starkly contrast with higher commercial plan costs, raising potential litigation risks. Consequently, the MFN deals led by industry giants Pfizer, Lilly, and Novo Nordisk are not only reshaping drug pricing and reimbursement but also triggering ripple effects across the broader healthcare ecosystem.

The FDA's April 30, 2026 decision to exclude semaglutide, tirzepatide, and liraglutide from the 503B Bulks List marks a definitive end to large-scale compounding of GLP-1 drugs, a practice that once accounted for roughly 30% of the US supply at its 2024 peak. Citing the availability of FDA-approved branded therapies, the agency explicitly rejected affordability and insurance access as valid clinical needs to justify continued bulk compounding, emphasizing that pricing and access issues fall under the purview of payers and policymakers rather than regulatory exceptions. This regulatory pivot transforms what was a temporary enforcement discretion during drug shortages into a permanent structural rule, fundamentally reshaping the compounding landscape and signaling a prioritization of safety and branded drug pathways over economic considerations.

The crackdown has sent shockwaves through telehealth platforms and cash-pay obesity clinics such as Hims, Ro, and LifeMD, which had built business models around the availability of lower-cost compounded GLP-1 therapies priced between $200 and $400 per month—substantially cheaper than branded options like Wegovy at approximately $1,349 monthly. Over 50 FDA warning letters issued in 2025 to compounders and telehealth distributors underscore the agency’s enforcement rigor, forcing these companies into a costly and strategic pivot towards branded therapies. While 503A patient-specific compounding remains legal, its limited scale cannot replace the industrial-level supply once provided by 503B outsourcing facilities, effectively ending the parallel compounded market that had expanded patient access through affordability.

This regulatory shift sets a foundational precedent that will reverberate through future debates on access to high-cost branded drugs, firmly establishing that bulk compounding under Section 503B is not a loophole for circumventing drug pricing but a pathway strictly reserved for clinical necessity or shortage scenarios. As the FDA’s stance clarifies, economic barriers alone do not constitute clinical need, a position that industry experts anticipate will be cited repeatedly in legal and regulatory arguments for years to come. Consequently, the crackdown not only reshapes current telehealth economics and supply chains but also signals ongoing challenges for compounded drug markets amid evolving drug approval processes and Medicare coverage reforms.

By early 2026, the GLP-1 therapy market is experiencing explosive growth, with adoption rates soaring from 5.8% to 12.4% of Americans within just over a year, fueled by the introduction of oral formulations such as Novo Nordisk's Wegovy pill and Eli Lilly's Foundayo. This surge is reshaping competitive dynamics as both companies leverage their extensive patent portfolios and innovative delivery models—including telehealth portals and subscription pricing—to enhance adherence and market share amid intense pricing pressures and patient sourcing challenges. Eli Lilly, in particular, is gaining ground on Novo Nordisk through advanced pipeline candidates like retatrutide, a multi-hormone agonist demonstrating up to 28.7% body weight reduction in Phase 3 trials, signaling a potential shift in market leadership and setting the stage for a projected $100 billion market by 2030.

Despite commanding high prices for blockbuster drugs like Wegovy and Ozempic, Eli Lilly faces growing competitive and regulatory headwinds as patients increasingly turn to gray market alternatives, challenging the sustainability of current pricing strategies. This tension is compounded by ongoing patent battles and lengthy FDA approval processes that shape the timing and scope of next-generation GLP-1 therapies entering the market. Meanwhile, both Novo Nordisk and Eli Lilly are intensifying lobbying efforts to influence drug pricing policies, reflecting strategic maneuvers to navigate evolving reimbursement landscapes and protect their market positions amid soaring demand and expanding indications beyond traditional diabetes treatment.

The competitive race is further heating up as key trial readouts from Pfizer, Viking Therapeutics, and Eli Lilly loom in 2026, with the potential to disrupt current market hierarchies by introducing next-generation obesity drugs that promise improved efficacy and patient experience. Eli Lilly’s retatrutide, in particular, stands out with its superior weight loss outcomes, potentially eclipsing existing GLP-1 leaders and solidifying Lilly’s dominance in a rapidly evolving landscape where innovation and clinical performance are paramount. This intensifying competition underscores a market in flux, where scientific breakthroughs and strategic positioning will determine the leaders in obesity and diabetes therapeutics for years to come.